The present invention provides an injectable liquid formulation with controlled release comprising: a) a lipid controlled-release matrix comprising at least 50% triacyl lipids； b) at least one oxygen containing organic solvent； c) at least 16% by weight of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. The invention also provides a method for the treatment of pain, for opioid maintenance therapy or for the treatment of opioid dependence by detoxification and/or maintenance or for the treatment or prophylaxis of the symptoms of opioid withdrawal and/or cocaine withdrawal by injecting such a liquid composition.
